Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| enVVeno Medical CorpNVNO · Entity 8104 | Chief Financial Officer | December 05, 2023 | December 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
enVVeno Medical Corp
Report date December 05, 2023 · Filed December 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2033-12-05 | Direct | 75,000 |
Reported balance
After 2023-12-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-05 · Grant · Acquired 75,000 · Balance 75,000 F1: The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2023 Filed Dec 7, 2023 17:07 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantStock Options · Derivative | 75,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001493152-23-044062 · ownership.xml · derivative · entry 1 Glynn Craig · CIK 0001809590 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-12-05 F1 · derivative.exercise_date: The common stock options were issued to the Reporting Person on December 5, 2023 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2026. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:25 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantStock Options · Derivative | 125,925 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001493152-21-030331 · ownership.xml · derivative · entry 2 Glynn Craig · CIK 0001809590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,925 Underlying: Common Stock · 125,925 shares Expires 2031-11-30 F2 · derivative.exercise_date: The common stock options were issued to the Reporting Person on November 30, 2021 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2024. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:25 UTC | enVVeno Medical Corp NVNO · Entity 8104 | GrantCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-030331 · ownership.xml · nonDerivative · entry 1 Glynn Craig · CIK 0001809590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The Reporting Person was granted 50,000 restricted stock units on November 30, 2021 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The restricted stock units are subject to milestone-based vesting as follows: (i) 50% upon SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) endpoints being achieved, and (ii) 50% upon the Pre-Market Approval of the VenoValve. Read SEC document |
| February 18, 2021 Filed Feb 23, 2021 17:21 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantStock Option · Derivative | 324,000 | $0.00 Strike: $8.20 | $0.00 |
DisclosureSEC source: 0001493152-21-004623 · ownership.xml · derivative · entry 2 Glynn Craig · CIK 0001809590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324 Underlying: Common Stock · 324 shares Expires 2031-02-18 F1 · security: The stock option was granted pursuant to the registrant's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). F3 · derivative.exercise_date: The stock options vest in equal quarterly installments over a three year period, however the stock options may only become exercisable following receipt by the registrant of stockholder approval to increase the size of the Plan sufficiently to permit the exercise in full of such stock options under the Plan. If the registrant's stockholders do not approve an increase in the size of the Plan, the options will be void. Read SEC document |
| July 18, 2020 Filed Feb 23, 2021 17:21 UTC | enVVeno Medical Corp HJLI · Entity 8104 | GrantStock Option · Derivative | 4,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001493152-21-004623 · ownership.xml · derivative · entry 1 Glynn Craig · CIK 0001809590 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires 2030-07-18 F1 · security: The stock option was granted pursuant to the registrant's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). F2 · derivative.exercise_date: The stock option vests in equal quarterly installments over a three year period commencing October 18, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.